[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529347":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":50,"collaborators":52,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":19,"enrollmentInfo":70,"targetDuration":19,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":19,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Singapore General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FET PET","EXPERIMENTAL","Upon recruitment, a single study visit will be scheduled where subjects undergo a limited 18F-FET PET\u002FCT of the brain in SGH.\n\nAfter the study visit, from time of recruitment, they will continue their regular clinic visits as clinically indicated, where they will be monitored for at least a year for stability or deterioration. If clinically indicated, they may undergo conventional MRI, alternative MRI imaging and\u002For histopathological correlation in their respective primary institutions.\n\nDuring these follow-up visits, any adverse effects possibly attributed to the 18F-FET PET\u002FCT can also be flagged up.\n\nAny alternative MRI imaging performed (as part of clinical practice in the respective primary institutions) within 4 weeks of the 18F-FET PET\u002FCT study will also be included in the comparative analysis.",[13],"Diagnostic Test: FET PET",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","There is only one study visit during which study subjects will undergo a 18F-FET PET\u002FCT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.",[9],null,[21,38],{"facility":22,"status":23,"city":24,"state":19,"zip":19,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"National Cancer Centre Singapore","RECRUITING","Singapore","SG",{"type":27,"coordinates":28},"Point",[29,30],103.85007,1.28967,{"lat":30,"lon":29},[33],{"name":34,"role":35,"phone":36,"phoneExt":19,"email":37},"Chua","CONTACT","65-96779867","kevin.chua.l.m@singhealth.com.sg",{"facility":5,"status":23,"city":24,"state":19,"zip":19,"country":24,"countryCode":25,"cosmosGeoPoint":39,"geoPoint":41,"contacts":42},{"type":27,"coordinates":40},[29,30],{"lat":30,"lon":29},[43,47],{"name":44,"role":35,"phone":45,"phoneExt":19,"email":46},"Lam","65-8123-0904","winnie.lam.w.c@singhealth.com.sg",{"name":48,"role":49,"phone":19,"phoneExt":19,"email":19},"Winnie W Lam, MBBS, FRCR, FAMS","PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[53,55,58],{"name":54,"class":6},"National Cancer Centre, Singapore",{"name":56,"class":57},"National Neuroscience Institute Singapore","UNKNOWN",{"name":59,"class":6},"Duke-NUS Graduate Medical School","100529347","phase-2-fet-pet-in-differentiating-tumour-progression-from-pseudoprogression-in-high-grade-glioma-100529347",false,"NCT06172595","FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma","18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas","FET PET in HGG","Inclusion Criteria:\n\n* Men or Women, aged 21 years or older at time of screening\n* Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour\n* With enlarging contrast-enhancing and\u002For T2W\u002FFLAIR-hyperintense lesion(s) on MRI within the previous RT field\n* Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry\n* Subject must consent to undergo all study procedures\n\nExclusion Criteria:\n\n* Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17\n* Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.\n* Proven cerebral metastases\n* IDH-mutated gliomas\n* Pregnancy\u002F breast-feeding","ALL","21 Years",{"count":71,"type":72},22,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\\[18F\\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \\[18F\\]FET-PET in delineating disease. The main question\\[s\\] it aims to answer are:\n\n* whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression\n* whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET\u002FCT of the brain in SGH.",[78],"Glioma, Malignant","2024-11-28",{"date":81,"type":82},"2024-12-03","ACTUAL",{"date":84,"type":82},"2023-12-21",{"date":86,"type":72},"2026-02-28",{"name":5,"class":6},2]